VAPOTHERM INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense
Depreciation and amortization
Provision for credit losses
Provision for inventory valuation
Gain on litigation settlement
Non-cash lease expense
Change in fair value of contingent consideration
Impairment of goodwill
Impairment of long-lived and intangible assets
Loss on disposal of property and equipment
Placed unit reserve
Interest paid in-kind
Amortization of discount on debt
Loss from deconsolidation
Deferred income taxes
Loss on extinguishment of debt

Changes in operating assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other assets
Accounts payable
Contract liabilities
Accrued expenses and other liabilities
Operating lease liabilities, current and long-term
Net cash used in operating activities
Cash flows from investing activities
Purchases of property and equipment
Acquisition of business, net of cash acquired
Net cash used in investing activities
Cash flows from financing activities
Proceeds from issuance of common stock and pre-funded warrants and accompanying warrants in private placement, net of issuance costs
Proceeds from loans, net of discount
Proceeds from revolving loan facility
Repayment of loans
Payments of debt extinguishment costs
Payment of debt issuance costs
Short-term line of credit
Proceeds from exercise of stock options and purchase of restricted stock
Repayments on revolving loan facility
Payment of contingent consideration
Proceeds from issuance of common stock in connection with at-the-market offerings, net
At-The-Market offering
Total proceeds from issuance of common stock in connection with at-the-market offerings, net

Proceeds from exercise of warrants
Proceeds from issuance of common stock under Employee Stock Purchase Plan
Proceeds from exercise of stock options and purchase of restricted stock awards
Common stock offering costs
Proceeds from exercise of stock options
Net cash provided by (used in) financing activities

Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash
End of year
Beginning of period
End of period

Supplemental disclosures of cash flow information
Interest paid during the period
Property and equipment purchases in accounts payable and accrued expenses
Issuance of common stock to satisfy contingent consideration
Issuance of common stock warrants in conjunction with long term debt
Issuance of common stock for services
Issuance of common stock upon vesting of restricted stock units
Issuance of warrants in conjunction with debt draw down

Comments